Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Epigenetics - levels of control
- The patient cancer journey-multiple impact points
- Key translational areas for epigenetics
- DNA methylation as cancer biomarker (1)
- DNA methylation as cancer biomarker (2)
- Detecting methylated DNA - NaHSO3 modification
- DNA methylation analysis methods
- DNA methylation
- Patient DNA methylation - potential clinical impact
- Gene body methylation - breast cancer vs. control
- Epigenetic gene silencing in malignant cells
- Progress in the management of ovarian cancer
- CpG methylation and clinical outcome
- Wnt pathways
- Causes of aberrant DNA methylation in cancer
- Stem cell targets
- Increases in side populations seen after treatment
- Gene expression changes in side population cells
- PRC2 - catalyses lysine methylation on histones
- EZH2 knockdown affects tumorigenic potential
- EZH2 as a potential anti-cancer target
- Epigenetic modification as drug targets
- Epigenetic therapies
- Epigenetic modulation of drug resistance
- DNA methylation versus platinum resistance
- Loss of MLH1 leads to drug resistance
- Phase II trial of Decitabine & Carboplatin
- Decitabine and Carboplatin in ovarian cancer
- Effects of low doses of DNA-demethylation agents
- Epigenetic therapies challenges
- Epigenetics unit teams and support
Topics Covered
- Epigenetics
- levels of control
- The patient cancer journey-multiple impact points -Key translational areas for epigenetics
- DNA methylation as cancer biomarker
- DNA methylation analysis methods
- Epigenetic gene silencing in malignant cells
- CpG methylation and clinical outcome
- Causes of aberrant DNA methylation in cancer
- Stem cell targets
- EZH2 as a potential anti-cancer target
- Epigenetic modification as drug targets
- Epigenetic therapies
- DNA methylation versus platinum resistance
- Phase II trial of Decitabine & Carboplatin
- Effects of low doses of DNA-demethylation agents
- Epigenetic therapies challenges
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Brown, B. (2012, September 27). Epigenetic biomarkers in cancer [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 4, 2024, from https://doi.org/10.69645/GQCB7308.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Bob Brown has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.